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Table 1. Demographics and baseline characteristics
Age (years) 78,5  7,6
Sex (M) 16 (44,4)
HT (%) 30 (83,3)
DM (%) 9 (25)
COPD (%) 18 (50)
PVD (%) 11 (30,6)
CABG (%) 9 (25)
Logistic Euroscore 36,4  14,3
Euroscore II 10,2  6,0
STS score 7,9  6,2
LVEF (%) 50,412,5
AV Area (cm2) 0,60,1
Peak AV Gradient (mm Hg) 75,714,3
Mean AV Gradient (mm Hg) 49,38,8
PAP (mm Hg) 45,312,6
HT¼Hypertension; DM¼Diabetes Mellitus; COPD¼Chronic Obstructive Pulmonary Disease;
PVD¼Peripheral Vascular Disease; CABG¼Coronary Artery Bypass Graft; LVEF¼Left Ventric-
ular Ejection Fraction; AV¼ Aortic Valve; PAP¼Pulmonary Arterial Pressure; AF¼Atrial Fibril-
lation; BBB¼Bundle Branch Block; PCI¼Percutaneous Coronary Intervention
Table 2. The types and sizes of the bioprotesis implanted and the femoral
access route
CoreValve 26 (%) 7 (19,4)
CoreValve 29 (%) 12 (33,3)
CoreValve 31 (%) 7 (19,4)
Edwards Sapien 23 (%) 1 (2,8)
Edwards Sapien 26 (%) 9 (25)
Percutaneous (Prostar XL) (%) 7 (19,4)
Surgical cut-down (%) 29 (80,6)
Table 3. Complications
Second valve implantation (%) 2 (5,6)
Vascular complication (%) 5 (13,9)
Paravalvular AR (< Mild) (%) 3 (8,3)
Stroke (%) 1 (2,8)
VSD (%) 1 (2,8)
All causes mortality (%) 4 (11,1)
Reversible LBBB (%) 3 (8,3)
Persistant LBBB (%) 5 (13,9)
Permanent Pacemaker 4 (11.1)
AR¼Aortic Regurgitation; LBBB¼Left Bundle Branch Block; VSD¼Ventricular Septal Defect
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Background: Combined surgical aortic valve replacement (SAVR) and coronary
artery bypass grafting (CABG) in patients with aortic stenosis (AS) and concomitant
coronary artery disease (CAD) is associated with increased operative risks. There is
little knowledge on the outcome associated with performing percutaneous coronary
intervention (PCI) in combination with transcatheter aortic valve implantation (TAVI).
Aim of Study: To investigate the outcome of combined TAVI and PCI in high-risk
patients with symptomatic high-grade AS and signiﬁcant CAD.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAMethods: From 1/2008 until 6/2012 338 consecutive patients (79.96.0 years,
logEuroSCORE 1811%) successfully treated with Medtronic CoreValve (n¼183),
Edwards-SAPIEN (n¼146) or Symetis Acurate bioprosthesis (n¼9) were
included in the analysis. 221 patients (66%) had CAD. 66 patients (19.5%, 33 female)
with signiﬁcant CAD underwent combined TAVI and PCI. In 58 patients (group A)
a staged approach of PCI a mean of 139 days prior to subsequent TAVI was chosen.
8 patients (group B) were treated in a single procedure with PCI ﬁrst. 272 patients
underwent only TAVI (group C).
Results: 30 daymortality for patients undergoing TAVI plus PCI was similar to patients
with isolated TAVI (12.1% vs. 9.9%; OR¼1.4, 95% CI 0.6-3.267; p¼0.436). 7 patients
(10.6%) of the TAVI plus PCI group had a periprocedural myocardial infarction
(NSTEMI) and stroke occurred in two patients (4.7%). There were no signiﬁcant
differences between TAVI plus PCI group vs. TAVI only group with regards to vascular
complications and postprocedure acute renal failure. Contrast volume at TAVI
implantation was higher in group B compared to group A patients (25160 vs. 17973
ml; p¼0.022).
Conclusion: CAD is frequent among patients with severe AS undergoing TAVI.
Revascularization with PCI can be safely performed in addition to TAVI either as
a staged or a concomitant intervention in this high-risk patient population.Pediatric Cardiology
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Introduction: Prostaglandin infusion treatment is of vital importance for keeping the
ductus arteriosus patency while waiting for either open surgery or invasive trans-
catheter intervention in duct-dependent congenital heart disease. Our study aimed at
deﬁning the lowest effective prostaglandin (PG) E1 dose in patients with inadequacy
of both pulmonary blood ﬂow and/or blood mixing (Group 1) and those with inad-
equate systemic blood ﬂow (Group 2).
Methods: Patients referred to our center within two weeks from birth following the
diagnosis of duct-dependent congenital heart disease and the start of i.v. prostaglandin
infusion were included in the study. Patients with inadequacy of both pulmonary blood
ﬂow and/or blood mixing (Group 1) and those with inadequate systemic blood ﬂow
(Group 2) were retrospectively evaluated in two separate groups with regard to the PG
E1 starting dose given in the referring facility, the lowest and the highest dose admin-
istered in our center, treatment duration, adverse effects and administered treatment.
Results: Of the 95 patients considered in the study, 69 (72.6%) belonged to Group 1
and 26 (27.3%) to Group 2. No difference between the groups could be detected as to
sex or birth weight (p¼0.95 and 0.42, respectively). A statistically signiﬁcant difference
could not be established for prostaglandin treatment duration, 9,730,81 days in Group
1 and 11.61.05 in Group 2 (p¼0.064). While the prostaglandin starting dose given to
both groups in the referring facility was 0.0670.003 mcg/kg/min, it was reduced after
titration to 0.0390.002 and 0.0810.005 mcg/kg/min, respectively, and this differ-
ence between the two groups was signiﬁcant (p<0.001). The dose administered to
Group 1 while ductus patency was being maintained was 0.00310.0001 compared to
0.00420.005 mcg/kg/min for Group 2, also a statistically signiﬁcant difference
(p<0.001). No adverse effects, including apnea, were observed during PG E1 infusion.
Conclusion: Our ﬁndings indicate that the infusion of prostaglandin at a very low
dose (0.003-0.005 mcg/kg/min) is sufﬁcient to maintain the patency of the ductus
arteriosus. A higher dose of PG E1 may be necessary in patients in patients with
inadequacy of both pulmonary blood ﬂow and/or blood mixing.
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Background and Aim: Congenital corrected transposition of the great arteries is
a group of clinically heterogeneous diseases because of numerous accompanyingLS C37
